BioVaxys Technology Corp. Summarizes Operating Initiatives After DPX™ Platform Integration

VANCOUVER, BC — December 31, 2025 — Leads & Copy — BioVaxys Technology Corp. is summarizing its operating initiatives over the past year, following the integration of the DPX™ platform into the BioVaxys business.

The company is focused on driving organic growth by expanding its early-stage pipeline through out-licensing opportunities and research collaborations where the DPX platform can address specific needs. BioVaxys aims to reduce internal risk and the funding requirements of late-stage clinical studies by out-licensing maveropepimut-S (MVP-S) in selected indications and seeking a co-development partner for DPX-formulations in infectious diseases. The company also plans to re-engage clinical trial investigators for continuations of phase 1 studies of DPX formulations.

The DPX platform is a major innovation in vaccine development that offers a solution to limitations faced by vaccines using other antigen delivery methods. It delivers active ingredients to the immune system using a novel mechanism of action that does not release active ingredients at the site of the injection, but rather forces an active uptake of immune cells and delivery into the lymphatic nodes. The programming of immune cells happens in vivo and offers a more efficient approach that mimics the natural function of the immune system. This "no release" mechanism allows for an active uptake of antigens into immune cells and lymph nodes for a sustained activation of the immune system in which the T cell flow is sustained over a longer duration than traditional vaccines on the market.

In 2025, BioVaxys enhanced its scientific and business development expertise through the addition of Dr. James Tartaglia to the Board of Directors, and Dr. Marianne Stanford as Scientific Advisor.

Dr. Tartaglia, an internationally recognized vaccine R&D leader with over 34 years of industry experience, recently retired as Global Head of Vaccine Development and Life Cycle Management for Sanofi. During his twenty-seven years at Sanofi, Dr. Tartaglia was responsible for a vaccine portfolio of 25 projects extending from phase I/II through life cycle management in the areas of influenza, pediatric combination vaccines, RSV, rabies, Yellow Fever, pneumococcal and meningococcal vaccines. Over his career, Dr. Tartaglia has been involved in the licensure of 20 vaccines in veterinary and human health. Prior to Sanofi, he was Executive Director of Research at Virogenetics Corporation, a former subsidiary of Sanofi Pasteur. At Virogenetics he helped develop the poxvirus vector technology as an immunization vehicle for both veterinary and human application, including HIV and cancer. He is an inventor on over 20 patents relating to recombinant vaccines and has authored over 130 publications in the areas of molecular virology and recombinant vaccine technology and participates as associate editor and/or reviewer for several peer-reviewed journals.

Dr. Stanford was Vice President of R&D at the former IMV Inc, where she and her team were responsible for the development of the DPX™ vaccine portfolio. Under her leadership, Dr. Stanford’s team also demonstrated that combining DPX, cyclophosphamide and then PD-1 blockade (using antibodies such as pembrolizumab, Merck’s Keytruda™) enhanced immunogenicity and thus efficacy in cancer models. Dr. Stanford and collaborators have published numerous studies and she is named inventor on multiple patents related to the DPX platform and DPX formulations. This includes patents that explore DPX compositions that express mRNA encoded by the nucleic acid components in targeted cells.

BioVaxys has been engaging in outreach efforts with major vaccine and pharma companies to introduce the DPX platform and explore research collaborations in the infectious disease field for its RSV and flu vaccine programs, as well as for new DPX-based formulations in cancer and viral diseases.

Earlier this month, BioVaxys announced positive results from a phase 1 clinical study of maveropepimut-S (“MVP-S”) along with neoadjuvant hormone therapy in women with hormone receptor positive HER2 negative (HR+HER2-) stage II-III breast cancer.

The clinical study demonstrated that BioVaxys' MVP-S in combination with letrozole generated a strong immune response in study participants with positive HER2 negative (HR+HER2-) stage II-III breast cancer. Patients in the study had at least a 50% decrease in Ki67 levels from median 24% before treatment to median 6% after treatment. One patient had an 8-fold increase of survivin-specific circulating Interferon-gamma (IFN-γ) T cells.

BioVaxys and the investigating team at Providence Cancer Center in Oregon now plan to further evaluate the systemic immunity of MVP-S and conduct expanded profiling of biopsy compared to post-treatment surgical samples, using the additional data to pursue a phase II study with MVP-S to modify the tumor immune environment in high-risk HR+ breast cancer.

In May 2025, BioVaxys and Sona Nanotech Inc. jointly announced that they entered into a research agreement to collaborate on the development of new cancer therapeutics based on the Company's DPX Immune Educating Platform in combination with Sona's Targeted Hyperthermia Therapy™ (“THT”).

To reduce internal risk and the considerable funding requirements of late-stage clinical studies, BioVaxys has been exploring out-licensing maveropepimut-S (MVP-S) in selected indications. In addition to previous licensing discussions this year, the Company has been in discussions with a global pharma company interested in licensing maveropepimut-S (MVP-S) for ovarian cancer.

The Company and a prospective partner in the animal health field have agreed to advance a research collaboration for a proof-of-product program to evaluate a DPX formulation of a proprietary mRNA sequence for diseases requiring long-duration protection such as rabies. The research agreement governing the collaboration is expected to be finalized and announced early 2026.

The Company is seeking a partner for further clinical development of its DPX-RSV for Respiratory Syncytial Virus (“RSV”), which successfully completed a phase 1 human study for safety and efficacy. DPX-RSV demonstrated antigen-specific immune responses in 93% of subjects, with 100% of responders in a 25μg single-dose cohort maintaining antigen-specific immunity one year post vaccination.

The Company has revenue generating licenses with Zoetis Inc. and SpayVac-for-Wildlife, Inc. for vaccines in the animal health field based on the Company's lipid encapsulation technology, with both licensors making excellent progress towards commercialization.

James Passin, CEO, stated, “In 2025, we have continued to build a world-class team of advisors and directors to help the Company develop and monetize its extraordinarily undervalued DPX IP portfolio. We look forward to advancing and crystallizing ongoing out-licensing and research collaboration discussions in 2026, a year in which we anticipate aggressive business development activity and booking our first royalty income.”

James Passin, Chief Executive Officer
Office Phone: +1 740 358 0555

Source: BioVaxys Technology